Step inside Humphrey & Beleznay Cosmetic Dermatology's clinical research practice.
Behind the scenes of our patient clinic’s elegant luxury is a world of scientific innovation and discovery led by a team of world-class researchers. Since 2000, our research team has completed more than 60 studies, involving over 1,900 participants and helping multiple products get to market, including; Belkyra, Botox, Juvederm, Latisse, Dysport, Xeomin, and Radiesse. In fact, we have enrolled more participants and successfully completed more studies than any other cosmetic research facility in Canada. This deep understanding of the science and evidence behind our treatments and products allows our staff to bring an unparalleled level of expertise to patients.
Interested in learning more about the globally recognized research conducted at Humphrey & Beleznay Cosmetic Dermatology? Here is a selection of the studies completed on-site by our clinical research team.
AbbVie
Phase 3, Multicenter Open-label Extension Study to Evaluate the Safety of BOTOX®
(Botulinum Toxin Type A) Purified Neurotoxin Complex for the Treatment of Platysma Prominence.
Galderma
A randomized, evaluator-blinded, parallel group, comparator-controlled, multicenter study to evaluate the safety and effectiveness of GP0112 for cheek augmentation and correction of midface contour deficiencies.
AbbVie
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex for the Treatment of Platysma Prominence
Galderma
A Pilot Study to Evaluate Safety and Effectiveness of Poly-l-lactic acid (PLLA) for the Improvement in Appearance of Cellulite.
Galderma
A Study Comparing Hyaluronic Acid Effectiveness & Evaluating Cheek Results with Restylane (CHEEKY Study)
Galderma
A randomized, evaluator-blinded, parallel group, no treatment controlled, multicenter study to evaluate effectiveness and safety of GP0109 for augmentation and correction of retrusion in the chin region
Revance
A Phase 2, Multicenter, Open Label Study to evaluate the Efficacy and Safety of DaxibotulinumtoxinA for Injection (DAXI for Injection) for the combined Treatment of Upper Facial Lines (Glabellar Lines, Dynamic Forehead Lines and Lateral Canthal Lines)
Galderma
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of QM1114-DP for the Treatment of Moderate to Severe Lateral Canthal Lines
Allergan
A Multicenter, Long-term, Open-label Study to Evaluate the Safety of MT10109L (NivobotulinumtoxinA) for the Treatment of Glabellar Lines and Lateral Canthal Lines
Allergan
BOTOX® (onabotulinumtoxinA) Treatment of Masseter Muscle Prominence: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study
Allergan
A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex for the Treatment of Platysma Prominence Protocol
Allergan
Canada Global HARMONY: Prospective, Multi-site, Study to Evaluate Subject Satisfaction with Facial Appearance Overall and the Aesthetic and Psychosocial Impact of Combined Facial Treatment
Allergan Inc.
MT10109L-005 A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of MT10109L (NivobotulinumtoxinA) for the Treatment of Glabellar Lines With or Without Concurrent Treatment of Lateral Canthal Lines
Revance Therapeutics
Protocol 1620303 An open-label, multi-center trial to assess the safety of single and repeat treatment of DaxibotulinumtoxinA for Injection for Treatment of Moderate to Severe Glabellar lines (SAKURA open-label safety)
Allergan Inc.
Protocol CMO-US-FAS-0486 Histological and Microbiological Evaluation of Late Occurring Nodules with Hyaluronic Acid Dermal Fillers
Revance Therapeutics
A Phase 2, Randomized, Double-Blind, Dose Ranging, Active and Placebo Controlled, Multi-Center Study to Evaluate the Safety and Efficacy and Duration of Effect of RT002, a Botulinum Toxin Type A for Injection, to Treat Glabellar Lines.
Completed 2015
Allergan Inc.
91622-130 Phase 2 study to evaluate the safety and efficacy of a range of doses of BOTOX for the treatment of subjects with bilateral masseter muscle hypertrophy (MMH)
Kythera Biopharmaceuticals, Inc.
ATX-101-13-35: A Multicenter, Double-blind, Non-treatment, Long-term Follow-up Study of Subjects who Completed the ATX-101 (Deoxycholic Acid Injection) Clinical Trials ATX-101-11-22 or ATX-101-11-23 for the Reduction of Localized Subcutaneous fat in the Submental Area.
Allergan Medical Inc.
Protocol: 192024-043: Bimatoprost for the Treatment of Eyebrow Hypotrichosis
Kythera Biopharmaceuticals
BELKYRA for Submental Fat (FDA Approved)
Protocol ATX-101-11-22: Multicenter, randomized, double-blind, placebo-controlled Phase 3 study of ATX-101 (sodium deoxycholate injection) versus placebo for the reduction of localized subcutaneous fat in the submental area.
Completed September 2013
Allergan Medical Inc.
GMA-BTXC-11-004: Long-Term Safety and Patient Satisfaction of Effectiveness of Facial Aesthetic Treatment with BOTOX®; A 10 Year International Experience.
Completed March 2013
Allergan Medical Inc.
Protocol: GMA-BTXC-10-002: A Multicenter, Double Blind, Randomized, Placebo Controlled, Parallel Group, Single Treatment Cycle Study of BOTOX® Cosmetic (Botulinum Toxin Type A) Purified Neurotoxin Complex in Subjects with Forehead and Glabellar Rhytides.
Allergan Medical Inc.
Voluma-002: A Multicenter, Single-blind, Randomized, “no-treatment” Control Study of the safety and Effectiveness of JUVÉDERM® VOLUMA XC Injection Gel for Cheek Augmentation to Correct Age-Related Volume Deficit in the Mid-Face
Allergan Medical Inc.
Protocol: 191622/099:A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex in Subjects with Facial Rhytides (Crow’s Feet Lines and Glabellar Lines)
Carruthers Dermatology Centre, Inc.
CDC 08-01: A Single Centre Controlled Comparison Study to Evaluate the Safety of Lidocaine 15% and Prilocaine 5% Topical Ointment used as Anaesthesia for Intense Pulsed Light Treatments.
Allergan Medical Inc.
Protocol:192024-032-00: A Multicenter, Double-Masked, Randomized, Parallel Study Assessing the Safety and Efficacy of Once-Daily Application of Bimatoprost Solution Compared to Vehicle in Increasing Overall Eyelash Prominence
Allergan Medical Inc.
No. 191622-075-00: A Multicenter, Open-Label Study of the Safety and Efficacy of Repeated Treatments with BOTOX (Botulinum Toxin Type A) for Primary Axillary Hyperhidrosis in Adolescents
Merz Pharmaceuticals GMBH
Protocol # 60201-0527/1: A prospective, randomized, double-blind, placebo-controlled, multicenter trial to determine the optimal dose of NT 201, free of complexing proteins, in the treatment of glabellar frown lines.
RJ Development
A Clinical Trial to determine the safety and effectiveness of microdroplet injections of SilSkin Silicone oil for HIV associated facial lipoatrophy.
Allergan Medical Inc.
Protocol No. BTX 9920, A Single Center, Pilot, Dose-Comparison Study of Safety and Efficacy of BOTOX Cosmetic (Botulinum Toxin Type A) in Female Subjects with Upper Face Rhytids
Allergan Medical Inc.
Protocol No. BTX 9917, A Long Term Safety Review of Subjects Treated with BOTOX (Botulinum Toxin Type A) for Cosmetic Use.
Allergan Medical Inc.
A multicentre, double-blind, randomized, placebo-controlled, parallel study of the safety and efficacy of repeated treatment with one or two doses of BOTOX (Botulinum Toxin Type A) Purified Neurotoxin Complex for the Treatment of Primary Axillary Hyperhidrosis Protocol No. 19162-016.
Allergan Medical Inc.
A prospective, double blind randomized, parallel group study analyzing the effect of varying BOTOX dilution in female subjects with glabellar rhytids.
Allergan Medical Inc.
A prospective, double blind randomized, parallel group, dose-ranging study of BOTOX in female subjects with horizontal forehead rhytids
Allergan Medical Inc.
A prospective, double blind, randomized parallel group, dose-ranging study of BOTOX in female subjects with glabellar rhytids.
Clinical Research Coordinator, LPN
Beauty philosophy: Beauty is the glow we give off when we find that place of self-love.